MOD GRF 1-29 2 mg Peptide Sciences
MOD GRF 1-29 2 mg from Peptide Sciences is a peptide that belongs to the GHRH group and promotes the natural production of growth hormone in the body of professional athletes. The drug has gained its popularity among most professional athletes who have received an award in relevant competitions.
MOD GRF 1-29 2 mg by Peptide SciencesProperties and impact in bodybuilding in England
To increase the half-life, 4 amino acids have been included in the sequence GRF 1-29 (which initially lasts half an hour). For steroid analogs, ModGRF 1-29 is closer in structure to testosterone propionate.
The average dosage of MOD GRF 1-29 is 150-200 μg per day. It is administered intramuscularly or subcutaneously. Pharma is diluted in water and stored in the refrigerator for 8-10 days, if the infection is diluted with bacterial water, storage can be extended up to 30 days (it is strictly forbidden to freeze the solution).
This drug is used to build muscles and give them relief and density, with a properly selected dosage, you can also get modern venosity, which indicates dry muscle mass.
You can buy MOD GRF 1-29 from Peptide Sciences in England on the site of our online store.
Main effects MOD GRF 1-29 by Peptide Sciences
- Increase in strength performance;
- Muscle growth;
- Fat burning.
Applications MOD GRF 1-29 2 mg in England
The optimal dosage of GRF (1-29) Mod is 100-200 mcg taken 1-3 times a day as subcutaneous or intramuscular injections. The total duration of the course is 6-12 weeks.
It is optimal to combine GRF (1-29) with taking peptides like GHRP in the next course:
- Sermorelin GRF (1-29) - 100-200 mcg;
- GHRP-6 or GHRP-2 - 100 µg;
- The peptides should be dissolved in 1-2 ml of water and injected 1-3 times a day;
- Optimal time of administration: 15 min before meals, immediately after training and before going to bed.
Buy MOD GRF 1-29 2 mg in England right now is quite simple, just place your order on our website.
There are no reviews for this product, be the first to leave your review.
